首页> 美国卫生研究院文献>Antimicrobial Agents and Chemotherapy >Activities of E1210 and Comparator Agents Tested by CLSI and EUCAST Broth Microdilution Methods against Fusarium and Scedosporium Species Identified Using Molecular Methods
【2h】

Activities of E1210 and Comparator Agents Tested by CLSI and EUCAST Broth Microdilution Methods against Fusarium and Scedosporium Species Identified Using Molecular Methods

机译:C12和EUCAST肉汤微稀释方法测试的E1210和比较剂对通过分子鉴定方法鉴定的镰刀菌和镰孢菌种的活性

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Fusarium (n = 67) and Scedosporium (n = 63) clinical isolates were tested by two reference broth microdilution (BMD) methods against a novel broad-spectrum (active against both yeasts and molds) antifungal, E1210, and comparator agents. E1210 inhibits the inositol acylation step in glycophosphatidylinositol (GPI) biosynthesis, resulting in defects in fungal cell wall biosynthesis. Five species complex organisms/species of Fusarium (4 isolates unspeciated) and 28 Scedosporium apiospermum, 7 Scedosporium aurantiacum, and 28 Scedosporium prolificans species were identified by molecular techniques. Comparator antifungal agents included anidulafungin, caspofungin, itraconazole, posaconazole, voriconazole, and amphotericin B. E1210 was highly active against all of the tested isolates, with minimum effective concentration (MEC)/MIC90 values (μg/ml) for E1210, anidulafungin, caspofungin, itraconazole, posaconazole, voriconazole, and amphotericin B, respectively, for Fusarium of 0.12, >16, >16, >8, >8, 8, and 4 μg/ml. E1210 was very potent against the Scedosporium spp. tested. The E1210 MEC90 was 0.12 μg/ml for S. apiospermum, but 1 to >8 μg/ml for other tested agents. Against S. aurantiacum, the MEC50 for E1210 was 0.06 μg/ml versus 0.5 to >8 μg/ml for the comparators. Against S. prolificans, the MEC90 for E1210 was only 0.12 μg/ml, compared to >4 μg/ml for amphotericin B and >8 μg/ml for itraconazole, posaconazole, and voriconazole. Both CLSI and EUCAST methods were highly concordant for E1210 and all comparator agents. The essential agreement (EA; ±2 doubling dilutions) was >93% for all comparisons, with the exception of posaconazole and F. oxysporum species complex (SC) (60%), posaconazole and S. aurantiacum (85.7%), and voriconazole and S. aurantiacum (85.7%). In conclusion, E1210 exhibited very potent and broad-spectrum antifungal activity against azole- and amphotericin B-resistant strains of Fusarium spp. and Scedosporium spp. Furthermore, in vitro susceptibility testing of E1210 against isolates of Fusarium and Scedosporium may be accomplished using either of the CLSI or EUCAST BMD methods, each producing very similar results.
机译:通过两种参考肉汤微稀释(BMD)方法对新型广谱抗真菌剂,E1210和比较剂进行了镰刀菌(n = 67)和镰孢菌(n = 63)临床分离株的测试。 E1210抑制糖磷脂酰肌醇(GPI)生物合成中的肌醇酰化步骤,导致真菌细胞壁生物合成中的缺陷。通过分子技术鉴定了镰刀菌(Fusarium)的5种复杂生物/物种(4种未指定菌株)和apispermum的28种Sedosporium apiospermum,7种Sedosporium aurantiacum和28种Scodosporium prolificans种。比较剂抗真菌药包括阿尼芬净,卡泊芬净,伊曲康唑,泊沙康唑,伏立康唑和两性霉素B。E1210对所有测试的分离物均具有高活性,E1210,阿尼芬净,卡泊芬净的最低有效浓度(MEC)/ MIC90值(μg/ ml)分别为0.12,> 16,> 16,> 8,> 8、8和4μg/ ml的伊曲康唑,泊沙康唑,伏立康唑和两性霉素B. E1210对Scedosporium spp非常有效。经过测试。 E1210 MEC90对于无子链霉菌为0.12μg/ ml,而对于其他受试药物,为1至> 8μg/ ml。针对S. aurantiacum,E1210的MEC50为0.06μg/ ml,而比较者为0.5至> 8μg/ ml。对抗S. prolificans,E1210的MEC90仅0.12μg/ ml,而两性霉素B> 4μg/ ml,伊曲康唑,泊沙康唑和伏立康唑则> 8μg/ ml。 CLSI和EUCAST方法对于E1210和所有比较器代理都是高度一致的。除泊沙康唑和尖孢镰刀菌种复合物(SC)(60%),泊沙康唑和金黄色葡萄球菌(85.7%)和伏立康唑外,所有比较的基本一致性(EA;±2倍稀释度)> 93%和S. aurantiacum(85.7%)。总之,E1210对耐 Fusarium spp的唑类和两性霉素B的菌株表现出非常有效的广谱抗真菌活性。和 Scedosporium spp。此外,E1210对 Fusarium Scedosporium 分离株的体外敏感性测试使用CLSI或EUCAST BMD方法均可完成,每种方法均产生非常相似的结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号